Stone House Investment Management’s Altimmune ALT Stock Holding History

Stone House Investment Management’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.62K	Buy	526 +26	+5%	+$110	﹤0.01%	628
2025 Q4	$1.8K	Hold	500	–	–	﹤0.01%	567
2025 Q3	$1.89K	Hold	500	–	–	﹤0.01%	494
2025 Q2	$1.94K	Hold	500	–	–	﹤0.01%	413
2025 Q1	$2.5K	Buy	+500	New	+$3.17K	﹤0.01%	370
2024 Q4	–	Sell	-500	Closed	-$3.07K	–	65
2024 Q3	$3.07K	Hold	500	–	–	﹤0.01%	310
2024 Q2	$3.33K	Hold	500	–	–	﹤0.01%	304
2024 Q1	$5.09K	Buy	+500	New	+$5.09K	﹤0.01%	288

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Stone House Investment Management's ALT Position: Q1 2026 in Review

Stone House Investment Management increased its Altimmune (ALT) stake by 5.2% in Q1 2026, buying an estimated $110 and bringing the position to 526 shares worth $1.62K. The position accounts for ﹤0.01% of the portfolio, ranked #628.

Stone House Investment Management first reported a position in ALT in Q1 2024 and has held it in 8 quarters since. The position peaked at $5.09K in Q1 2024. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.

Stone House Investment Management held 526 shares of Altimmune worth $1.62K as of Q1 2026.
Stone House Investment Management bought 26 Altimmune shares in Q1 2026, an estimated $110.
Altimmune made up ﹤0.01% of Stone House Investment Management's portfolio in Q1 2026, its #628 holding.
Stone House Investment Management first reported a position in Altimmune in Q1 2024 and has held it in 8 quarters since.
Stone House Investment Management's Altimmune position peaked at $5.09K in Q1 2024.
173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.

Based on Stone House Investment Management's 13F filing for Q1 2026, filed 22 Apr 2026.